A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I always get an uneasy feeling when I green thumb a stock like Protalix because I don't trust the company and I especially don't trust former chairman Philip Frost. Does he still have his fingers in this pie? Your guess is as good as mine. As far as I'm concerned, nothing he is involved with is investment grade. That being said, the company has managed to get a potentially lucrative drug approved and they have the ability to compete with the established therapies due to lower manufacturing costs. This could certainly blow up disastrously but I'm willing to kick in an outperform pending initial sales data.
ZZ,
Good morning.
Can you share more about aversion to Frost?
I know just the superficial and his current involvement with TEVA which I follow.
Thank you.
azinsd
http://seekingalpha.com/article/454261-opko-health-highly-questionable-management-transactions-and-valuation
If you were holding shares of Protalix in October 2007 you would have a strong and lasting aversion to Philip Frost, not that I was.